Arcturus Therapeutics News and Activities

Arcturus Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Arcturus Therapeutics is a company listed under the stock ticker ARCT (US).

View the org chart displaying its 32 main executives

Most searched biographies at Arcturus Therapeutics

• Joseph Payne, Director, President and Chief Executive Officer
• Jing Marantz, Director
• Magda Marquet, Director

Popular executive movements at Arcturus Therapeutics

• Andrew Sassine, Chief Financial Officer and Director, will leave the company on Dec. 31, 2025  (posted on December 16 2025).

Create your alert
to follow the executive moves at Arcturus Therapeutics.

Arcturus Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Arcturus Therapeutics

• Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Arcturus Therapeutics, Inc.
• Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study | Arcturus Therapeutics, Inc.
• Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update | Arcturus Therapeutics, Inc.
• View more press releases Close

Social media about Arcturus Therapeutics

• Arcturus Therapeutics on Wikipedia, Google News & Yahoo Finance
• Arcturus Therapeutics on LinkedIn, X (Twitter) & YouTube